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business it is to commercially 
scale new products. 
4. Transfer 
technology to one 
or more public 
institutions, such 
as a government 
agency 
 Public institution could 
potentially maintain quality 
standards and control over 
usage of technology. 
 Access to public financial 
resources. 
 Government would have 
stronger incentives to 
implement regulations and 
laws to enforce aflatoxin 
contamination minimums 
and create compliance 
incentives to buy Aflasafe. 
 More closely aligned with 
IITA’s social impact 
mission than private sector 
actors. 
 Most governments do not 
have the business skills or 
agility to operate like a 
results-oriented private sector 
business. 
 Governments should already 
be incentivized to implement 
and enforce aflatoxin 
regulations. 
Tested as an option in 
Kenya, with little 
success. Very difficult for 
public institution to 
manufacture, market, 
and distribute efficiently 
and effectively, and fully 
invest in the facility and 




 Relationship with 
distribution partner allows 
IITA and the partner to test 
the market potential for 
Aflasafe over a limited 
duration of time before a 
longer-term commitment. 
 IITA maintains control of 
manufacturing process, 
ensuring quality control 
and quantity to meet 
demand. 
 Reduces risk for IITA and 
distribution partner before 
the former commits to a 
manufacturing partner and 
the latter commits to a 
significant financial 
investment. 
 In the long term, not in IITA’s 
interest, nor a fit with their 
institutional mission, to 
manufacture products for 
public sales. 
 May lead to disagreements 
and negotiations regarding 
certain types of costs, such 
as who will fund marketing 
efforts and how the product 
will be branded. 
 Creates negative incentive for 
distributor to ever invest in 
manufacturing or take on 
longer-term risk if they are 
already making an acceptable 
margin on distribution. 
Currently being tested as 
option in Ghana and 
Burkina Faso. Potential 
interim solution when a 
manufacturing partner is 
not available or a good 
fit, but not a long-term 
solution. Questions 
regarding sharing costs 
and responsibilities, 
marketing, and 
engagement with third 
parties should be 
discussed before a 
limited license is 
executed. IITA should 
evaluate if they have the 
time and resources for 
















control, sales, and 
marketing. Partner 
makes a financial 
investment and 
commitment to the 
Aflasafe business. 
 Allows IITA to focus on 
core mission of research 
and improving the Aflasafe 
technology and solution. 
 M&D partner brings their 
investment and expertise 
in manufacturing, 
marketing, and other 
business functions. 
 Licensing allows IITA to 
remain involved in the 
business; hence, can 
monitor their goal of 
maximizing uptake by 
those who are most 
vulnerable to aflatoxin 
poisoning. 
IITA retains a royalty fee, 
and M&D partner captures 
profit margin as sales 
increase. 
 Difficult to change course if 
M&D partner is 
underperforming given 
significant investor selection 
process, due diligence 
required, and financial 
investment by the partner. 
 IITA has to staff and maintain 
a highly skilled team to 
closely work with, support, 
and monitor the performance 
of the M&D partners.  
Win-win relationship, 
where each party 
focuses on what they are 
good at. Most realistic 
option, given IITA’s 
mission and structure. 
Licensing is a logical 
compromise between the 
original CGIAR mandate 
and strategy to work 
through private sector on 
commercializing 
Aflasafe.  
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V. Commercialization Partnership Options for Aflasafe 
The potential alternatives for commercializing new innovations and/or new technologies are 
outlined in the exhibit below in no particular order. As indicated in this analysis, IITA and the 
Advisory Board determined there was only one viable option in a given situation—licensing the 
technology to a commercial company. While the preferred option is to grant a license to a 
private sector partner to both manufacture and distribute Aflasafe (Option 6 below), IITA is also 
testing an alternative option: to grant a license to a distributor on a trial basis through a limited 
distribution, limited duration license (Option 5). 
 
Exhibit 5. Commercialization and Partnership Options for Aflasafe 
Options Pros Cons Determination by IITA 
1. Open Source 
license  
Available to whomever wants 
to replicate the Aflasafe 
manufacturing process and 
distribute through 
commercial or subsidized 
channels. 
 Process to share mother 
culture would require 
significant vetting. 
 Changes in manufacturing 
process could decrease 
Aflasafe’s efficiency, thus 
hurting its reputation.  
 Would still require registration 
country-by-country, which 
may be difficult if not 
sponsored by an international 
research institution like IITA. 
Unrealistic option given 
complexities of the 
Aflasafe technology. 




process to one 
company 
IITA could potentially 
demand a high price for the 
technology and reinvest the 
funds into future innovations, 
without the need to remain 
involved in the continual 
improvement of Aflasafe. 
 IITA would not be able to 
ensure that quality standards 
for Aflasafe are maintained. 
 Impossible to be sure if 
marketing interventions will 
target smallholders who are 
most at risk of aflatoxin 
contamination. 
 No guarantee that the private 
sector partner would invest in 
continuous product 
improvements instead of 
maximizing profit margins. 
Option does not fit the 
values and mission of 
IITA, nor its objective 
with Aflasafe to share 
lessons learned, 
continuously improve the 
production process, and 
expand use of Aflasafe to 
new crops through more 
testing. 











 IITA would maintain quality 
standards and control over 
usage. 
 IITA retains all profits long-
term to finance research  
 IITA maintains operational 
control of all elements of 
research, production, and 
commercialization. 
 Insufficient working capital or 
financial structure to 
indefinitely support the 
business operations of 
scaling Aflasafe production 
and investing in marketing 
strategies and distribution 
channels. 
 Would shift IITA into an 
international business instead 
of a non-profit research 
institution, requiring 
significant changes—from 
how the product is registered 
to obtaining tax-free status, 
diplomatic status, and status 
as a CGIAR institution.  
 Fails to leverage the 
resources and experience of 
the private sector, whose 
Unrealistic option as it is 
not feasible within IITA’s 
structure, and would 
entirely change the 
organization’s mission, 
mandate, and operations 
structure. Also, does not 
fit within the classification 
of IITA as a non-profit 
institution. Taxes are not 
levied on products 
developed by IITA in the 
IITA-controlled 
production facilities. 
Attempting to operate a 
business circumventing 
taxes would jeopardize 
IITA’s legal standing and 
primary mission as a 
research institution.  
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participants be given the opportunity to ask questions. Another important session is an 
introduction to Aflasafe by a member of the IITA research team, with a focus on the science 
behind the product and the manufacturing process, although be careful to avoid lingering too 
long on the science and research background at the expense of emphasizing the business 
opportunity Aside from those two sessions, organizing breakout sessions is critical to the forum. 
Participants can be split into discussion groups (e.g., firms interested in manufacturing, potential 
buyers, and members of enabling environment) and be asked to discuss tailored questions on 
the key challenges for Aflasafe uptake. Participants should also be provided a list of input 
assumptions from the financial analysis and be asked for their feedback on whether they 
consider them to be reasonable (see IITA database/toolkit for sample breakout session 
questions).  
 
Depending on feedback received from participants, you may need to revise certain assumptions 
you made when preparing the commercialization strategy, analyzing information, and forming 
your recommendations. Some of the slides may need to be refined even after IITA leadership 
has reviewed and approved the commercialization strategy to reflect new information shared by 
the stakeholders attending the forum. For example, manufacturers or agribusinesses may have 
more accurate manufacturing cost or sorghum price information than you were able to gather 
during desk and field research, and updating these figures could impact rates of return or the 
time horizon until an Aflasafe investor would break even. Another example is learning about an 
aflatoxin risk or Aflasafe incentive that a market segment faces that was not previously 
considered, such as the cost of aflatoxin testing for a specific processor, which could impact 
prioritization of core market segments. If post-forum revisions are required, be sure to 
recirculate the commercialization strategy to IITA leadership, flagging the updates.  
 
Use the opportunity provided by the investor forum to start compiling a list of firms who you think 
have the right profile to become investors in manufacturing and distribution of Aflasafe in the 
target market (see tip box). Firms that send C-suite executives 
who actively participate in sessions can be a good indicator of 
their level of interest, and side-conversations can help gather 
details that will be useful for the investor selection stage. 
However, be sure not to make any promises or commitments 
about a future role in Aflasafe commercialization; a competitive 
and transparent selection process is important for getting the 
eventual buy-in of Aflasafe buyers and government 
champions.  
 
The process for competitively and transparently selecting an 
investor can begin now that you have developed a detailed 
and insightful Aflasafe commercialization strategy for your 
target market that has been reviewed by key stakeholders. The final output of the investor forum 
is a questionnaire tailored to the private sector asking them to indicate if they are interested in 
investing in Aflasafe production, and if so, what additional information they may need to make 
an informed decision. A review and filtering of the questionnaire and investor forum outputs will 
be the first step for selecting an investor to manufacture and distribute Aflasafe in the target 
market.   
  
Tips and Tricks  
 
Organize one-on-one meetings 
with businesses showing the most 
potential as investors, and large 
potential buyers of Aflasafe. 
These organizations can be 
identified earlier in the process. 
These meetings will help 
establish initial relationships 
critical to keep momentum going 
after the forum. 
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Holding an investor forum is a crucial part of launching commercialization of Aflasafe in the 
target market. It will be your team’s first formal marketing and communications opportunity to 
promote Aflasafe as a new innovation in the target market that can bring financial value to users 
and provide wider social and health benefits for the population. The forum will bring together 
members of the commercialization team, IITA leadership, local authorities, regulators, and key 
players in the maize, groundnuts, and/or agricultural inputs industries. Be looking to achieve the 
following objectives when planning the forum: 
 Increase awareness of the science behind Aflasafe and its potential to resolve aflatoxin 
issues 
 Validate key assumptions in the commercialization strategy  
 Respond to questions and feedback on the strategy to increase its credibility 
 Receive informal expressions of interest from businesses who may invest in 
manufacturing and distribution  
Once logistics are sorted out for the forum, the commercialization team should publicize the 
event and invite a wide array of actors and stakeholders to attend (see lessons learned box). 
Document all invitations that are sent and follow up at 
least once with high-level participants and potential 
investors, as you want to avoid accusations of leaving 
someone out or playing favorites. Some examples of 
potential invitees include: 
 Actors from the long list for interviews, particularly 
those who indicated interest in the product or 
investing in Aflasafe  
 Firms who have formally expressed interest in 
investing 
 Key members of each market segment 
 Members of the scientific community working on 
Aflasafe/aflatoxin 
 Government stakeholders, such as ministers of agriculture, environment, and health or 
their representatives 
 International community members and donors, such as USAID, AGRA, PACA, UN, WFP 
 IITA representatives, in country and regionally 
 Media, who can be helpful in promoting the forum and Aflasafe 
The media is a critical invitee to the investor forum, and engagement with media contacts and 
journalists should begin as soon as an investor forum date is selected. IITA should prepare a 
press release to be distributed to media contacts that summarizes the aflatoxin issue, the 
science behind Aflasafe and its potential impact, the intention of IITA to award a license for 
manufacturing and distribution of Aflasafe, and any other important details relevant to the target 
market context. Scoring a media posting in a national publication about a week prior to the 
investor forum could drum up interest, ensure attendance by high-level participants, and even 
start increasing market awareness and demand for Aflasafe; be sure to share the press release 
or story with your invitees. 
 
The larger the attendance at the forum, the more feedback you will receive on the strategy and 
the wider pool of investors potential investors. While the format of the forum can vary, it is 
essential that the executive summary of the commercialization strategy be presented and 
Lessons Learned  
 
It is critical to have the right balance of 
representation across stakeholders, 
with an emphasis on members of the 
business community. In Tanzania, 
discussions during the forum leaned a 
little too heavily on the scientific 
aspects of Aflasafe. During an investor 
forum, business aspects should be 
emphasized to get investors excited. 
See IITA database/toolkit for a sample 
forum agenda. 
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Acronym List 
 
ATTC Aflasafe Technology Transfer and Commercialization 
BCC  Board of Cereal Crops 
BIP  Business Incubation Platform 
COGS  Cost of Goods Sold 
EGAD  USAID Global Bureau’s Center for Economic Growth and Agriculture 
Development  
FAOSAT  Food and Agriculture Organization Corporate Statistical Database  
GAIN  Global Agriculture Information Network 
ha   hectares 
IA  Intellectual Assets 
IITA  International Institute of Tropical Agriculture 
IP  Intellectual Property  
M&D  Manufacturing and distribution 
MT  Metric tons 
NFRA National Food Reserve Agency 
PACA  Partnership for Aflatoxin Control in Africa 
R&D  Research & Development 
ROI  Return on Investment  
TTLA  Technology Transfer Licensing Agreement 
USAID  United States Agency for International Development 
USDA  United States Department of Agriculture 
WFP  World Food Program 
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I. Introduction 
The International Institute of Tropical Agriculture (IITA) has developed a unique solution, 
Aflasafe, to address aflatoxin contamination in major staple cereal crops in Africa. Through 
more than a decade-and-a-half of research and development, IITA and its partners have 
developed this product by identifying friendly fungi that are highly effective at reducing aflatoxin 
levels, then testing them in farmers’ fields. This testing has helped IITA create the best 
composition of Aflasafe for each country while providing data needed for the registration and 
regulatory process. The widespread application of Aflasafe in aflatoxin-affected areas has the 
potential to significantly increase quantities of aflatoxin-safe maize, sorghum, and groundnuts, 
and significantly reduce health effects of aflatoxin, including stunting in children and liver cancer. 
Through Aflasafe, IITA seeks to contribute not only to improving food safety but also increasing 
the income of smallholder farmers.  
 
To achieve these goals, IITA must widely deliver Aflasafe to agricultural value chain actors. 
However, developing an extensive production, distribution, and marketing operation throughout 
Africa to commercialize Aflasafe is not in line with the CGIAR Intellectual Assets (IA) Principles 
or the mandate of IITA as a non-profit research institution. After considering various options for 
manufacturing and distribution, IITA decided to pursue Aflasafe commercialization, led by the 
private sector and supported by the public sector, to turn this scientific innovation into a 
commercial product.  
 
Exhibit 1. Science to Scale Commercialization 
 
 
To facilitate the commercialization process, IITA received a grant from the Bill & Melinda Gates 
Foundation and the United States Agency for International Development (USAID) for 
implementation of a five-year initiative entitled Aflasafe Technology Transfer and 
Commercialization (ATTC), which is managed by IITA through the Business Incubation Platform 
(BIP). IITA hired Chemonics International, Inc. and Dalberg Advisors to support the 
implementation of ATTC. Aflasafe commercialization began in 2016 and has since expanded. 
Aflasafe is currently commercially registered and available in seven countries: Burkina Faso, 
The Gambia, Ghana, Kenya, Nigeria, Senegal, and Tanzania. As of October 2019, 12 more 
countries across Africa are at different stages in the pipeline for eventual Aflasafe 
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3. Economic rationale for Aflasafe uptake forecast 
 Is there a premium for Aflasafe treated products?  
 What substitutes are competitive and what are Aflasafe’s advantages over them?  
 Are there any major initiatives by the public or private sector on Aflatoxin? 
 Are there any major movements by public and non-profit sector around aflatoxin? 
4. Market segment analysis 
 Who are the key market segments?  
 What is each of their potential and forecasted demand?  
 How should they be prioritized? 
5. Manufacturing analysis based on financial model 
 What is the level of investment required? 
 When can an investor expect to break even? 
 What level of production is required to meet demand? What size and number of plants 
are right to meet this demand? 
 How should Aflasafe be priced? What are potential break-even prices under a variety of 
scenarios?  
6. Interventions to increase uptake  
 What interventions are already ongoing?  
 What “quick wins” exist to quickly achieve sales? 
 How can buyers of Aflasafe be recruited? 
 How can awareness be raised among the population and market segments? 
7. Potential investors 
 What investors have already expressed interest? 
 Who are businesses with the potential to invest in Aflasafe, and what are their respective 
strengths and weaknesses? 
 What role might the public sector need or want to play 
in production of Aflasafe? 
 
Once the draft Strategy is completed, submit it to IITA 
leadership and key stakeholders for feedback or approval (see 
box). Certain questions from IITA leadership or stakeholders 
regarding the analysis or recommendations contained in the 
Strategy may require follow-up with key informants or other 
stakeholders, so be sure to maintain relationship established 
through interviews and other discussions.  
Step 9. Hold Investor Forum 
 
Objective Present the draft commercialization strategy to a wide audience of actors operating in 
the target market, solicit feedback, fill any remaining gaps, validate key assumptions, 
and begin 1-on-1 conversations with investors to determine level of interest 
Things to keep in 
mind 
 Who is attending and why are they important to Aflasafe commercialization? 
 What are the key messages? 
 What conclusions reached are based on data or assumptions that should be 
validated by participants? 
 What facts will participants want to know before investing in Aflasafe? 
Projected timeline 
and resources 
2 weeks of part-time prep work by Strategy Manager and Associate. Recommended 
to hire a short-term consultant or task an operations colleague to handle logistics. All 
strategy team members to attend the forum 
 
Tips and Tricks 
 
Consider synthesizing the Strategy 
into a two-page document with the 
key findings and translate it into the 
local language. The two-pager will 
be easier to disseminate to the 
target audience prior to the 
investor forum, and pique the 
interest of serious investors. See 
the IITA database/toolkit for a 
sample summary. 
Market Assessment and Strategy Development / Page 31 of 36
 
The final deliverable of commercialization strategy development is 
a Strategy Document, typically compiled in PowerPoint format 
(see box). The Strategy is a compilation of all findings and key 
information gathered throughout the desk research, interviewing, 
and modeling process. Most importantly, it should present a 
convincing case for why a potential partner should invest in 
Aflasafe’s production and distribution for the target market. The 
Strategy should be presented in a highly polished and 
professional format, with an emphasis on data, analysis, findings, 
commercialization options and recommendations, to catch the 
attention of potential investors, the advisory board, and the wider 
audience that your recommendations for Aflasafe 
commercialization are well thought out and backed by data. 
 
Table 5. Commercialization strategy to Document Audience Profiles 
Audience Why are they reading? What are they reading? 
Potential Investors Determine if Aflasafe is a business 
opportunity with more rewards than 
risks 
Economic rationale, market 
segmentation, manufacturing analysis, 
interventions to increase uptake 
Advisory Board Evaluate if strategic approach for 
entering a new market is well 
thought-out and meets ATTC’s 
priorities 
Entire document 
Government Counterpart Learn more about Aflasafe and how it 
may be introduced to the national 
market and how this can help the 
general public 
Country context, economic rationale, 
interventions, and potential investors 
Donors Learn how Aflasafe could solve public 
health issues or increase incomes for 
smallholder farmers, and what donors 
can do to help 
Country context, economic rationale, 
interventions to increase uptake 
IITA Learn how their science can be 
brought to scale within a country 
context they know very well 
Country context, interventions, potential 
investors 
 
From a strategic perspective, recommendations should involve some degree of prioritization in 
terms of market segments to focus on, robust evidence to justify this prioritization, and an 
indication of what this means for the phasing of next steps (sample strategies available in the 
IITA database/toolkit). 
 
Each target market is different, and thus the deliverables will vary widely in conclusions and 
recommendations. However, strategies should be sure to include the following sections so that 
the documents present a complete picture of the potential market and commercialization 
opportunity: 
 
1. Executive Summary 
 If a reader only reads this section, what key information should they know about the 
Aflasafe opportunity in the target market? 
2. Country context 
 What is the total addressable demand?  
 What are the target market’s unique dynamics? 
 
Tips and Tricks 
 
Complete slides as you go! As 
your team starts the 
commercialization strategy 
process, familiarize yourselves 
with the strategy document 
template and fill out sections as 
you gather data and flesh out 
the financial model. This will 
save time down the road and 
ensure no key points are 
forgotten. 
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commercialization: Benin, Burundi, Cameroon, the Democratic Republic of the Congo, Ethiopia, 
Malawi, Mali, Mozambique, Rwanda, Zambia, Uganda, and Zimbabwe. In each country, ATTC 
researches the potential for commercialization, identifies and attracts potential investors, 
transfers the Aflasafe technology to an investor, and supports the manufacturing, distribution, 
and marketing efforts in such a way that the Aflasafe product will be available locally in an 
economically viable, sustainable, and independent way for many years to come.  
 
To enable the continued commercialization of Aflasafe and potentially support IITA or other 
CGIAR institutions in commercializing other products in the future, IITA, Chemonics, and 
Dalberg, under ATTC, have created four guides which outline the core processes of 
commercialization, i.e., how to take scientific research products to market. These guides include 
Market Assessment and Strategy Development, Investor Selection, Structuring the Business 
Relationship, and Implementation of the Business Development Strategy. A summary of the four 
guides is presented below in the order of the commercialization process. 
 
1. Market Assessment and Strategy Development: This guide describes the process 
that the ATTC initiative created for developing a commercialization strategy for Aflasafe, 
demonstrating how it can become a marketable farm input for sale in a specific country. 
The guide introduces the concept of commercialization and how it relates to IITA’s 
activities, outlines the desired outcomes of the market assessment and strategy 
development process, and suggests steps to be taken to develop a high-quality 
document featuring findings and conclusions backed by data—including the country 
context, market analysis, forecasts of Aflasafe uptake, a review of manufacturing 
potential, and identification of potential investors. The process should take approximately 
4-6 months in total—if assigned to a dedicated team with no unforeseen delays. Once 
the commercialization strategy is in place, there should be a clear understanding of how 
to commercialize Aflasafe in the country by prioritizing core market segments that are 
sensitive to aflatoxin and thus more likely to adopt Aflasafe. The strategy also informs 
the capacities and expertise needed by an investor to undertake manufacturing, 
marketing, and distribution. 
 
2. Investor Selection: This guide discusses the ATTC initiative’s recommended process 
for sourcing potential partners, analyzing investor options, and ultimately selecting the 
investor(s) in a specific country with the best potential for success in the manufacturing, 
marketing, and distribution of Aflasafe. The initial ideas for partner identification will be 
generated during the strategy development process, with multiple submissions from 
partners and reviews by IITA, culminating in a final selection by an advisory board based 
on presentations and recommendations. The selection process should take 
approximately 4-6 months if completed efficiently and without delays.  
 
3. Structuring the Business Relationship: This guide shares the ATTC initiative’s 
experiences navigating CGIAR policies and practices and partner motivations to 
structure a business relationship with the private sector investor selected to become the 
manufacturing and distribution (M&D) partner for Aflasafe. It provides guidance to a non-
legal audience on crafting the legal document needed for the transfer of the Aflasafe 
technology: a Technology Transfer Licensing Agreement (TTLA). The guide covers why 
this type of license agreement was selected by IITA as the core legal document for the 
process, provides questions to consider when tailoring the TTLA template, and offers 
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insights into negotiations with M&D partners to date. The TTLA process can take 1-2 
months, depending on the level of negotiation required. 
 
4. Implementation of the Business Development Strategy: This guide captures ATTC’s 
experiences working with the selected M&D partner to hand over valuable business 
knowledge developed throughout this process. This guide provides background 
information, lessons learned, and the recommended process for developing the key 
deliverables, including consumer profiles of potential buyers, a business case for the 
marketing of Aflasafe, and a handover memo for the selected partner. The guide 
addresses each of the key sections of these documents and shows their importance in 
facilitating the marketing and sales of Aflasafe to potential buyers. The development, 
consolidation, and handover of this information should take a total of 3-4 months using 
the standardized templates and tools.  
 
Please note that these guides are not exhaustive manuals, and thus should not be considered a 
complete list of steps to take. Also keep in mind that the approaches and guidance should be 
modified and contextualized for each target market and adjusted for changing dynamics. The 
guides have been designed with Aflasafe in mind but may be a starting point to adapt for other 
IITA or CGIAR products. As such, we have included considerations for products beyond 
Aflasafe throughout the guides. 
 
This guide goes into detail on the recommended steps to be taken by a strategy development 
team to assess a specific market for Aflasafe and develop a complete commercialization 
strategy. The steps, research questions, and suggested outputs reflect a process tried and 
tested over three years by the Dalberg, IITA, and Chemonics team in developing 
commercialization strategies for Aflasafe in Burkina Faso, The Gambia, Ghana, Kenya, Nigeria, 
Senegal, and Tanzania.  
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Analysis Key Questions Answered Why It’s Important 
Plant capacity 
 How many hours/shifts per day and 
days per year must a plant be active 
in order to meet demand under each 
scenario?  
 What does this mean in terms of the 
size of the plant that should make up 
the initial investment?  
 Should additional capacity be added 
after? 
Establishes what annual Aflasafe output must be to 
meet demand scenarios, which will influence plant 
size, operating costs, and any planned increases in 
capacity (through plant size or output). For 
example, in Kenya, the team had to choose 
between recommending two small plants (one near 
Aflasafe demand and one near sorghum 
production) vs one central plant; the key question 
to analyze was whether savings in transportation 
costs outweighed the extra fixed costs of a 2nd 
plant, at the expected demand level. 
Plant location 
 Where is demand for Aflasafe 
concentrated?  
 Where is the supply or sorghum 
concentrated?  
 Are there multiple planting seasons 
across the target market 
Determines strategic and cost significance of plant 
location, from its distance to markets, suppliers, 
distribution channels, or investor HQ. For example, 
in Nigeria, the team had to choose between 
recommending a plant in Lagos (where 
manufacturers have existing operations) vs in the 
North near sorghum production and Aflasafe 
demand. The team had to analyze whether 
transportation cost savings where outweighed by 
the cost of building new storage facilities in the 
North. 
Cost of inventory 
 What are the warehousing costs 
associated with holding and 
managing unsold inventory? 
Analyzes additional costs should sales not keep up 
with production. For example, in Kenya, there was 
a long gap between sorghum purchase and the 
second Aflasafe sale season, meaning sorghum 
needed to be held for up to 8 months. Financing 
this inventory added more than 10% to the break-
even cost of Aflasafe. 
Breakeven 
sensitivity 
analysis (or other 
sensitivity) 
 What combination of price and 
Aflasafe sales would an investor need 
to reach a certain return on 
investment? 
 What combination of assumptions 
affects another key metric?  
Helps quantify tradeoffs between two varying 
assumptions, and how they affect key financial 
metrics (e.g., how does price and uptake 
assumptions affect cashflow or return on 
investment (ROI)? How does the cost of capital (%) 
and number of plants affect annual cost of capital 
($) or ROI? For example, in Senegal the team 
needed to choose between recommending a small 
modular plant vs a large plant. The larger plant was 
cheaper per MT of capacity, but it was unclear if all 
the capacity would be used. The analysis revealed 
that a small plant was better (i.e., lower breakeven 
price) in the conservative and baseline demand 
scenarios, while the two strategies were equal in 
the upside scenario. Because the larger plant was 
always equal or worse than the smaller plant, we 
recommended the smaller plant. 
 
Step 8. Draft Strategy Document 
 
Objective Synthesize findings into a digestible document 
Things to keep in 
mind 
 Who is the target audience (e.g., Advisory Board, investor forum participants, 
government)? 
 Would readers want to invest in Aflasafe? 
 What key information gathered in research and interviews needs to be conveyed? 
Projected timeline 
and resources 
Each section/slide should be assigned to a team member, who will have 1 week to 
complete their draft, 1 week feedback round, and 1 week to finalize 
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Excel-based financial modeling, or at the very least have a high level of comfort with complex 
Excel spreadsheets (see tips box).  
  
The model is only as good as the data entered into it. It’s 
critical that you start making note of key data points from 
the desk research stage, continue gathering data 
through interviews, and revise data and assumptions as 
more information is collected. Key data points that 
should be gathered are: 
 Capital expenditures, such as purchasing the 
land, warehouse, and equipment required for 
Aflasafe production. This should be prepared by your Engineer. 
 The unit costs of goods sold (COGS) to produce 1 kg of Aflasafe, the most important 
COGS being white sorghum. The cost of casual labor for production and packing is also 
included in this calculation. This should be reviewed by your Engineer. 
 Personnel costs required to run a plant, along with information about whether any 
personnel costs might increase if production increases (e.g., having to add a second 
supervisor or technician over a certain production threshold). 
 Other business costs, such as maintenance, depreciation, taxes, and financing. 
 Implied/equivalent total hectarage of maize or groundnut production per market segment 
based on demand and, and average yield per crop (note that yield can vary widely on 
large or small farms). 
 Required rate of return (i.e., cost of capital) in the target market.  
While COGS and cost of capital are important for accuracy of the financial model, forecasted 
revenues will have a much larger impact on income statements. To forecast revenue as 
accurately as possible, establish a list of key market segments and distribute the total market 
demand across them. 
 
 Once a basic financial model is completed with input assumptions and revenue forecasts 
based on uptake scenarios, the financial modeler and the rest of your team can 
determine what other analyses are required to refine the strategy and anticipate investor 
questions. Some examples of additional analyses are shown in Table 4 below, but the 
Financial Modeler and strategy team should consider other possible analyses based on 
the key questions and hypotheses raised during the research process.  
Table 4. Financial Analysis Exercises to Consider during Modeling 
Analysis Key Questions Answered Why It’s Important 
Pricing scenarios 
 What is a breakeven price on different 
time horizons? 
 What types of costs, margins, or 
assumptions are driving up the price? 
Establishes if breakeven price meets the market’s 
pricing expectations, or what margins/costs need to 
be reduced (or could be increased) to meet 
affordable target price. For example, in Senegal, 
we modeled break-even prices under various 
demand scenarios and found that the target price 
for Year 1 (at 600MT / yr) was $1.40 / kg, but with 
a sustained push to increase demand to 5x that, 
the break-even price could be reduced to $1.00 / 
kg. 
Tips and Tricks 
 
One team member should “own” the 
model and share versions on a regular 
basis. Financial models are complex, 
and a minor unintended change can 
have a major impact on the accuracy 
of calculations. Delegating model 
responsibility to one team member 
reduces the risk of mistakes. 
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II. Overview of the Market Assessment and Strategy Development 
Why commercialization? 
 
Commercialization is the process of making a new product available on the open market. The 
majority of innovations are created in a research laboratory or workshop, which are controlled 
environments and require significant resources to run and operate. While research funding can 
be obtained from a range of different sources, commercializing innovations is a way to earn 
revenues from selling to targeted customers/buyers, which can then help fund more research. In 
addition to financial incentives, entrepreneurs or research organizations can experience societal 
benefits if the innovation has a social impact, reputational benefits if the innovation attracts 
publicity and is popular, and rewarding partnerships as the entrepreneur engages with the wider 
market. One of the primary objectives at the start of the ATTC initiative was to determine the 
commercial value for Aflasafe, and how to work with the private sector to get this product to 
market. There was significant interest and discussion prior to the start of the ATTC initiative 
among the CGIAR institutions, donors, economists, and government liaisons weighing various 
options for how to get a product with health, social, and economic benefits to the market. The 
commercialization partnership options for Aflasafe are summarized at the end of this guide, in 
Section V, providing insightful background if you are curious to explore alternative approaches.  
 
In the case of Aflasafe, a strongly advocated alternative to commercialization was making 
Aflasafe a public good and using donor or public resources to distribute it widely, either through 
IITA directly, through local governments, or a combination of the two. Many believed this was—
and continues to be—the best way to ensure distribution directly to smallholder farmers who are 
the most vulnerable to aflatoxin-related health risks. However, making a product free doesn’t 
mean the product is available to everyone, nor does it mean it will be valued or used, and it also 
ties uptake of Aflasafe directly to the unpredictable availability of philanthropic funding or 
subsidies from governments already strapped for resources. Private sector-driven 
commercialization was determined to be the best approach for treating the maximum number of 
hectares (ha) with Aflasafe, as profitability is a proven incentive to catalyze private financing to 
market a new product. IITA’s approach is to leverage the power of the free market supported by 
appropriate policies, while also structuring deals to ensure that Aflasafe is accessible to those 
who need it.  
 
Partnering with the private sector to scale the manufacturing and distribution allows limited 
CGIAR funds to be used primarily to support scientists in the development of the product, and 
prove its efficiency, before the necessary proof and protocols are transferred to a private sector 
partner. Working within market forces fosters market-driven demand and a business approach 
to distribution that focuses first on the target segments willing to pay for Aflasafe. This enables 
the private sector partner to reinvest and expand distribution channels and marketing to reach 
second- and third-tier markets. Getting the goods to the last mile, an original and continual goal 
of IITA, is only possible by working through and with the private sector. Without regenerating 
financial support, established and sustainable distribution channels, and innovative marketing 
strategies, scaling will be limited and the product will face an untimely demise.  
 
Successfully working with and through the private sector creates a cycle of financial support to 
regenerate and sustain the operations, while simultaneously allowing IITA to maintain credibility 
by focusing on producing high-quality innovations and research rather than chasing a profit 
margin and diverting resources from early-stage innovations. Thus, developing a strong 
economic case for Aflasafe and properly executing commercialization can be much more 
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effective and sustainable than donor-driven “push”-centric models, which often have limited 
longevity beyond the initial donor support. 
Why commercialize through a license with a private sector company? 
 
There is a variety of paths entrepreneurs can take when determining how to introduce a new 
product or technology to the public and grow its utilization. An innovator could decide to 
manufacture and distribute the product itself to maintain control of the process and key 
decisions—but they would need to have the business acumen and resources to start and 
manage a business. Or, an innovator could sell the rights to the technology, thereby cashing in 
on its intellectual property—but then they would have to renounce decision-making rights and 
the ability to maintain quality standards.  
 
Thus, following careful internal deliberations when Aflasafe reached the proof of concept stage, 
IITA determined that a Technology Transfer and Licensing Agreement (TTLA) is the best 
instrument for commercialization of Aflasafe. A license maintains IITA’s umbrella ownership of 
Aflasafe’s intellectual property and ensures quality control over a product whose manufacturing 
process has been refined and calibrated by scientists and engineers. The decision is also in 
accordance with CGIAR’s Principles on the Management of Intellectual Assets1 and reflects the 
public good potential of Aflasafe. For more information about the CGIAR management 
principles, please follow the hyperlink above or the website link in the footnote at the bottom of 
this page; for information about the TTLA, please see the guide on Structuring the Business 
Relationship; and for the analysis of various licensing options with private sector partners, 
please see the Investor Selection guide. 
What is the goal of a commercialization strategy? 
 
The commercialization strategy is the first step in taking a private sector approach to 
disseminate Aflasafe to farmers. It is the roadmap IITA used—and will continue to use—to 
understand the drivers of demand and the practicalities of supplying to meet demand, with the 
overall goal of maximizing uptake of Aflasafe. At this stage, the research & development (R&D), 
proof of concept, and registration/patent work has already been completed for Aflasafe, so the 
focus can now turn to understanding the market dynamics and economics that potential private 
sector manufacturing and/or distribution partners will want to know prior to investing in a factory 
and marketing efforts. 
 
The goal of developing a commercialization strategy is to answer three questions:  
1. What is the rationale for users to purchase and companies to invest in an innovation like 
Aflasafe?  
2. What does this rationale suggest for which market segments will drive demand?  
3. Based on expected demand, what are the manufacturing and distribution options? 
Once these questions are thoroughly researched and answered, and the findings synthesized 
into a formal document, the Strategy can be used as a roadmap during the commercialization 
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 Downside scenario: Based on unanticipated shocks or obstacles that bring demand 
below the conservative scenario, which may be the case in terms of economic 
recession, emergence of a new substitute, reduced demand for the target crop, etc. In 
this scenario, uptake might be limited to 30% or less even for very motivated market 
segments with a strong economic interest, 10-20% for market segments with some 
economic interest, and less than 5% for market segments with mainly a non-economic 
interest such as health. These estimates are only guidelines and are highly dependent 
on country context. For example, an actor supplying WFP might have very high uptake 
even in a downside scenario. 
Developing different uptake estimates will allow for effective contingency planning based on 
forecasted return on investments across scenarios. During the financial modeling step, being 
able to quickly compare scenarios will help you determine how profitable Aflasafe can or cannot 
be based on the model’s input assumptions and how quickly you expect Aflasafe uptake to be 
across segments.  
Step 7. Conduct Analysis and Financial Modeling  
 
Objective Answer the following: 
 What is a realistic unit price range for Aflasafe in the target market? 
 How much will it cost to set up a manufacturing plant in the target market? How 
much will it cost to run? 
 When can a business investing in a plant expect to break-even at certain price 
ranges and sales scenarios, and will Aflasafe be affordable? 
Things to keep in 
mind 
 Has input data been validated by more than one source? 
 Are assumptions reasonable and defensible? 
 Does the target market have any complexities (like different sorghum and maize / 
groundnut seasons, multiple centers of demand located far apart) that would 
require special analysis? 
Projected timeline 
and resources 
Financial Analyst owns a complex financial model for the entirety of the strategy 
development process. Engineer to provide inputs on production assumptions 
 
 
A financial model is a tool, generally built in Microsoft Excel, to forecast a business’ financial 
performance in the future based on existing data and informed assumptions. In the case of 
Aflasafe, a financial model is used to generate five-year financial statements based on the costs 
of setting up and running an Aflasafe manufacturing plant, and anticipated revenue generated 
from Aflasafe sales. The output of a financial model will help you answer some guiding 
questions many of which investors will ask when gauging their interest in a partnership. 
 
The ATTC team has already created a financial model template tailored for Aflasafe and built to 
answer the aforementioned questions if populated with the correct data. While a template may 
be available, it is highly recommended that those working on the model have experience with 
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Table 3. Sample Aflasafe “Liberal” Uptake Scenario for Tanzania’s Market Segments 
Segment Info Uptake, % Uptake, MTs of Aflasafe 
Segment Area (HA) Y1 Y2 Y3 Y4 Y5 Y1 Y2 Y3 Y4 Y5 
Institutional 
buyers 42,857  30% 40% 60% 70% 75% 129  171  257  300  321  
Industrial 
processors 
(breweries) 10,000  30% 40% 60% 70% 75% 30  40  60  70  75  
Animal feed 
processors 428,571  5% 10% 20% 30% 40% 214  429  857  1,286  1,714  
Medium maize 
processors  600,000  0% 0% 5% 10% 10% -  -  300  600  600  
Groundnut 
processors  70,526  0% 0% 5% 10% 10% -  -  35  71  71  
On farm 
consumption - 
maize 2,714,286  0% 0% 5% 5% 10% -  -  1,357  1,357  2,714  
On farm 
consumption - 
groundnuts 692,632  0% 0% 5% 10% 15% -  -  346  693  1,039  
Total 4,558,872           372 640 3,213 4,376 6,534 
 
Develop at least two uptake scenarios to adequately plan for different adoption rates across 
segments as Aflasafe is introduced to the market. Each scenario will have varying percentage 
uptake assumptions by segment to reflect optimistic vs. pessimistic forecasts of Aflasafe sales. 
It is advisable to name each scenario for ease of reference and discussion among team 
members (see lessons learned box). Some example scenarios used for previous strategies 
were:  
 
 Liberal: Based on adoption rates driven by public and private sector interventions, such 
as increased aflatoxin awareness campaigns, establishment and enforcement of 
regulatory standards, public-good/ subsidized Aflasafe for identified markets. In this 
scenario, uptake could be as high as 75-100% for very motivated market segments with 
a strong economic interest, as high as 30-40% for market segments with some 
economic interest, and as high as 10-20% for market segments with mainly a non-
economic interest such as health. However, it’s 
important to realize that these estimates are only 
guidelines and are highly dependent on country 
context. For example, very remote smallholders in 
a large country might have low or no adoption even 
in a liberal uptake scenario. 
 
 Conservative: Based on adoption rates that would 
be observed if market is expected to drive demand. 
Assumes minimal aflatoxin awareness, non-
regulation of domestic consumption, limited 
availability, accessibility and affordability (non-
subsidized) of Aflasafe. In this scenario, uptake 
could be as high as 40-50% for very motivated 
market segments with a strong economic interest, as high as 20-30% for market 
Lessons Learned  
 
Smallholder farmers will tend to have 
by far the highest addressable 
demand hectarage. Thus, 
adjustments in uptake of even 
fractions of a percentage for this 
market segment can have an impact 
on estimated sales and financial 
projections. Given smallholders’ low 
economic incentives and willingness 
to pay for Aflasafe, be particularly 
careful estimating smallholder 
uptake of Aflasafe.  
segments with some economic interest, and as high as 5-10% for market segments with 
mainly a non-economic interest such as health. 
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Why is commercializing Aflasafe so complex? 
 
Aflasafe is a difficult product to sell, primarily because most potential users and many 
consumers of affected crops are unaware of the aflatoxin problem, and see no need to 
purchase a “solution” for a problem they don’t believe exists. Although anecdotal reports by 
farmers indicate an increase in yields, the product is not designed to directly increase yields and 
long-term data is not available to show a link between Aflasafe use and an increase in farmer’s 
yields. Instead, Aflasafe’s purpose is to combat aflatoxin, which is an often-unknown form of 
crop contamination that has three challenging features: 
1) It normally cannot be seen by the naked eye.  
2) It contributes mainly to very long-term damage that has yet to be publicly recognized as 
an issue by many local governments, let alone costed out by public health experts.  
3) It may be amenable to treatment by other practices or products (toxin binders, good 
agricultural practices) that may already be prevalent in the market, thus calling into 
question the need for a specific anti-aflatoxin product.  
Because of the absence of an immediate impact of aflatoxin, and the lack of a proven yield 
increase from Aflasafe, a typical smallholder farmer is not likely to prioritize spending any of his 
or her limited input budget on Aflasafe. Furthermore, given the obligation of IITA to protect 
product quality, years of testing and trials are required for each country-specific strain of 
aflatoxin, and so Aflasafe cannot simply be manufactured in bulk and distributed internationally. 
The highly technical science behind Aflasafe means that registration and public-sector 
involvement in commercialization are steps that must be navigated carefully as mistakes can 
mean months or years of delays in product approval and go-to-market.  
 
To attract potential private sector partners to invest in Aflasafe you will need to demonstrate the 
economic value; quantify the potential demand; identify the missed market opportunities; and 
show the potential return on investment after investing in the production, distribution, and 
marketing of the product. One of the first questions IITA hears when explaining the value of 
Aflasafe is “Who will buy Aflasafe and why?” Scientists have attempted to extensively 
demonstrate the benefits of Aflasafe and the significant breakthrough it represents, but without 
knowing how that translates into economic impact—science-led dissemination efforts have been 
largely ineffective (or at scale); in some cases, these efforts failed to attract potential M&D 
partners and may even have turned off potential processor and farmer customers. In many 
countries, the economic value is not easily recognizable, which is why we have explained the 
approach to conduct detailed economic research and analysis in this guide and subsequent 
guides.  
 
However, before being able to recognize the positive economic incentives of using Aflasafe, 
potential partners and buyers must already be aware of the risks of aflatoxin contamination. 
Thus, market prioritization of those who are already aware of aflatoxin risk or whose businesses 
are experiencing the negative effects of contamination is key; experience shows that uptake of 
Aflasafe will largely depend on promoting success stories from one or more “first mover” 
champions who integrated Aflasafe into their supply chains. From Day 1 of launching the 
commercialization process, your team should seek to determine who these champions will be 
by segmenting demand into different types of market actors, each with different characteristics. 
For more information on market segmentation see Section IV. Process, Step 6 and see the 
guide on the Implementation of the Business Development Strategy for our recommended 
process on recruiting buyers. 
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Since Aflasafe is so difficult to sell, we needed a strong methodology and approach to 
developing a comprehensive commercialization strategy. Other BIP innovations, such as bio-
stimulants and improved seeds, will be easier to sell given their direct impact on yields and plant 
survival rates. IITA is still in the learning process of commercializing Aflasafe and in the process 
of completing the initial five-year licensing and investment plans for Kenya, Nigeria, Senegal, 
and Tanzania. While the methodology used to date and outlined below was the starting point, 
this process will be continually refined as IITA gleans additional lessons learned, gathers 
economic impact and sales data, and receives feedback from investors. 
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Table 2. Total Addressable Demand (hectares) by Tanzania’s Seven Market Segments 
Legend: X=desk research, Y=field research, Z=analysis 






of maize (WFP, 
National Food 
Reserve Agency 
(NFRA) and the 
Board of Cereal 
Crops (BCC)) 
Suppliers of the main institutional buyers (WFP, 
NFRA and BCC) e.g., Musoma Foods;  
NFRA sells 80% of its maize to WFP (average 2,800 
MT/year), so not included in the estimate of the 
segment total;  
60,000 1.40 42,857 
Industrial 
processors of maize 
(breweries) 
Contract farmers of the main Tanzania's breweries 
(Tanzania Brewery Ltd. and Serengeti) who are 
either contracted directly by the breweries or 
indirectly through their key suppliers 
14,000 1.40 10,000 
Animal feed 
processors 
Farmers who grow maize for animal feed 600,000 1.40 428,571 
Medium maize 
processors  
Farmers who grow maize and sell to medium 
processors  840,000 1.40 600,000 
Groundnut 
processors  




Farmers who produce maize mainly for consumption 




Farmers who produce groundnuts mainly for 
consumption at home 658,000 0.95 692,632 
Total   6,039,000 4,558,872 
 
 
Once the market demand is segmented, make informed assumptions about the percentage of 
each market segment that will be purchasing Aflasafe in years 1 through 5. This exercise should 
be based on the initial hypothesis exercise, desk research, and informant interviews. Based on 
the commercialization team’s work to date, the assumed percentage of uptake should be based 
on how strong the risks and perceived incentives are for each segment. For example, 
institutional buyers face higher risks if they do not control for aflatoxin than medium-sized maize 
processors do, and thus we would expect higher uptake percentages and/or faster increases in 
uptake over years 1 to 5 for the institutional buyers segment. 
 
The total addressable demand for each segment, multiplied by the percentage of that segment 
who is expected to purchase Aflasafe, will equal the Aflasafe sales forecast. For the calculation, 
note that the application rate for Aflasafe is 10 kg per hectare, or 0.01 MTs per hectare. So, a 
segment with an addressable demand of 100 hectares and with 100% likelihood to purchase 
Aflasafe will equal a sales forecast of 1 MT of Aflasafe. An example of how this works in 
practice is given on the following page in Table 3 (note, all segment information linked to Table 
2). 
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Step 6. Segment the market into demand scenarios 
 
Objective Develop scenarios for what types of buyers will drive Aflasafe sales, and how quickly 
those buyers are likely to adopt Aflasafe 
Things to keep in 
mind 
 When data is not readily available, are informed assumptions made can be 
defended logically? 
 What is the rationale behind uptake assumptions? 




Brainstorming session by entire strategy team over 1-2 day after desk and field 
research are completed. Segments and scenarios should constantly be refined as the 
team gathers more information or gleans new insights 
 
Revisit your market segments and their risks/incentives—this was first addressed in Step 2 (and 
should have been revisited and refined many times since then!). Now begin brainstorming how 
to assign the total addressable demand in the target market across the segments. Some things 
to keep in mind when assigning addressable demand to market segments include: 
1) Normally, total addressable demand is just the total land area planted with maize plus 
the total land area planted with groundnuts (in ha) in the target market. We describe 
addressable demand in hectares (rather than MT of crop) because Aflasafe quantities 
are sold in based on the land area to which the product will be applied. 
2) If a market segment is defined by a buyer type rather than a farmer type, you will 
probably start with a figure in MT—for example, 60,000 MT of maize in Market Segment 
“X.” You will therefore need to convert this to hectares of production area. The simplest 
way is to use the average yield for that segment—for example, if buyers (like brewers) in 
Market Segment X normally buy from commercial farms with a yield of 2.0 MT/ ha, then 
Market Segment X represents 30,000 ha of addressable demand. It’s fine to use the 
average national yield in the absence of regional specific information. 
3) It is very important that all the segments be discrete insofar as they add up to the total 
hectares of production in the target crop, and no hectare appears in more than one 
group—which would create a double-count of addressable demand. Continuing with the 
example above, imagine that you think “large farms” are another market segment, and 
there are 100,000 ha of large farms in your target market. But you have already 
assigned 30,000 ha of maize to Market Segment X, and you think that this maize is 
grown by large farmers, so you need to remember to subtract this 30,000 ha—leaving 
only 70,000 ha in the general “large farms” market segment. 
 
Table 2 shows the output of the market demand segmentation exercise for Tanzania’s 
commercialization strategy. Based on desk research (see blue-colored numbers in table), the 
Tanzania team identified a few critical data points: Tanzania’s recent annual production of 
maize was 5,314,000 MTs and 725,000 MTs for groundnuts (making a total addressable 
demand of 6,039,000 MT of target crops), average yields were 1.4 MT/ha for maize and 0.95 
MT/ha for groundnuts, and about 3.8M MTs of maize are consumed on the farm. While this data 
was a good start, it left considerable gaps regarding how the remaining maize and groundnuts 
were distributed across the other segments. Determining how to distribute the remaining MTs of 
maize and groundnuts was one of the primary objectives of desk research. For example, based 
on interviews, the team learned that about 60,000 MTs of maize per year were bought by 
institutional buyers, and the feed industry processed about 600,000 MTs/year. While the 
Tanzania team did not glean any specific data for the other segments’ total MTs, the team was 
able to approximate distributions for the rest of Tanzania’s maize and groundnuts across 
segments by analyzing existing information and relying on the expertise of the team members.  
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III. Roles and Responsibilities 
The commercialization strategy team should include several core functions and skillsets. Individuals 
with complementary functions, and varying experiences, insights, and aptitudes, are needed. IITA 
and other members of the CGIAR System Management Organization are internationally renowned 
scientific research institutions conducting cutting-edge research in the areas of food security, health 
and nutrition, and resilient natural resources. However, these institutions historically have not had a 
mandate to commercialize their innovations and thus have not directly employed personnel with 
extensive business strategy experience and acumen. It behooves IITA and the other CGIAR centers 
to partner with similarly strong, internationally recognized external consultancy and strategy 
companies to assess market demand. One could even argue that without two separate institutions 
with complementary skillsets, there could be a conflict of interest or insufficient distance from the 
innovative product to conduct an unbiased analysis of the market potential of a new product. In 
order to complete each step in the process detailed below, be sure to identify and mobilize the 
requisite human resources.  
 
Exhibit 2 below outlines the essential roles and responsibilities, but keep in mind that different 
resources may be required based on the specific needs of a particular country. The list below does 
not indicate the role best associated with an external consulting team, but ideally, at least three of 
the agribusiness, strategy, and financial team members will be employed by a company external to 
IITA for this initial analysis. The Team Leader, Strategy Manager, and Financial Analyst will play 
important ongoing roles throughout the strategy development process, supported by other key roles. 
Exhibit 2. Illustrative Roles and Responsibilities for Market Assessment and Strategy Development 
Role Illustrative Skills Responsibilities 
Team Leader Expertise in agribusiness market 
dynamics, strong management skills 
Overall quality control of the process. Liaison 
with partners 
Strategy Manager Experience in private sector 
engagement, knowledge of field 
research practices, critical thinking  
Coordinates and contributes to each step of the 




Experience in international 
development and economic research 
Supports the Strategy Manager with research 
tasks, brainstorming, and operational tasks 
Financial Analyst Mastery of Excel, understanding of 
corporate finance principles 
Own financial model, identify data gaps, and 
develop financial slides 
Scientist Involvement in Aflasafe R&D and/or 
testing, as well as prior product 
development in the country 
Provides key information and fact checking on 
science behind Aflasafe  
Engineer Expertise in Aflasafe manufacturing  Provides financial analyst with initial investment 
required for Aflasafe production, and verifies 
other cost inputs as well as cost of establishing 
the Aflasafe factory. Advises on design as well 
as instrumental in initial technology transfer 
training 
Advisory Board Individuals mostly from outside your 
organization who bring diverse 
experience in agribusiness, science, 
experienced business acumen,  
financial analysis and donor 
representative perspective 
Periodic validation of outputs on a TBD 
schedule. Approves final strategy document. 
Serves as external checks and balances 
consistently across each market assessment and 
strategy development process, ensuring that 
lessons learned are applied.  
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IV. Process 
The commercialization strategy process described in the following sections is about defining the 
market opportunities for Aflasafe, designing interventions to seize those opportunities, and 
convincing the private sector to invest in manufacturing and distribution. It is an iterative 
process. As shown in Exhibit 3 below, this guide attempts to break the components of the 
process into manageable steps for users who may be new to commercialization and private 
sector partnership development.  
Exhibit 3. Market Assessment and Strategy Development Process 
 
As you reference this guide, keep in mind several general objectives for the strategy 
development work:  
 Gathering basic information to gauge the overall market for Aflasafe. 
 Gathering intelligence to logically segment the market for Aflasafe and formulating some 
hypotheses about what might drive members of each segment to buy Aflasafe. 
 Understanding the risks of incentives faced by buyers of crops susceptible to aflatoxin 
(i.e., maize and groundnuts) and formulate hypotheses about their awareness and 
motivation for dealing with Aflasafe.  
 Understanding the key players in the value chain, and the role of government, to ensure 
that your team speaks to the right people during field visits. 
Using this guide for developing a commercialization strategy for a product other than Aflasafe 
will come with its own challenges, as you will need to develop hypotheses on the economic 
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The interviews are your opportunity to validate, reject, or refine 
the hypotheses established on Day 1 in terms of the structure 
of the value chain for the target crops, the risks and incentives 
Aflasafe presents, and what these perceived risks and 
incentives suggest for the size of key market segments that can 
drive uptake. There may be various interpretations of data or 
anecdotes gathered during interviews, so it is very important to 
triangulate data where possible and carry out regular (ideally 
daily) syntheses of emerging findings so that subsequent 
questions seek to build out and refine analyses and ultimately 
recommendations (see below for possible structure of a daily 
update). 
 
While waiting for responses on interview request letters (see lessons learned box below), 
develop interview questions based on the key informant categories established in the last 
phase, the interview objectives for each category and based on gaps in the desk research 
phase (sample questions available in the IITA database/toolkit). When conducting interviews, a 
team of two helps ensure a maximum amount of content is recorded. One team member can 
focus on asking questions, the other on notetaking. 
 
When conducting interviews, feel free to go beyond your interview questions! If you hear an 
interesting piece of information, ask follow-ups to get to the heart of the issue and gather the 
maximum amount of data possible. This may be the only opportunity you have to be in a room 
with the informant. Be alert if you hear the following things during the interview—and probe 
deeper when you hear them: 
 Someone has incentive structures to help 
commercialize Aflasafe in the target market 
 Someone is paying a price premium for aflatoxin-free 
target crops 
 Someone might be interested in investing in Aflasafe 
manufacturing 
 Some company / government body is testing for 
aflatoxin in the target market 
 Someone is trying to build awareness among farmers 
/ consumers for aflatoxin 
 Someone has found success using other methods 
(including traditional) to combat aflatoxin 
The interviewers should share updates with the wider team on a daily basis, as interviews are 
completed. This is particularly important if there are multiple interview teams or supporting team 
members who have begun work on the analysis. Contents of a daily update may include: 
 Key challenges for Aflasafe 
 Key opportunities  
 Data and numbers to be used for analysis 
 Remaining gaps in understanding 
 New interview leads 
Lessons Learned  
 
Trying to get a meeting with a high-
level informant or someone critical 
to gleaning a missing piece of 
information or data? Ask someone 
else to reach out or make a 
connection through their network. 
Heavy hitters, such the Director, 
Advisory Board member, Members 
of the Strategic Partners team or 
IITA leadership might help you get 
in the door you might not be able to 
open on your own.  
Tips and Tricks 
 
Managing the logistics for 
interviews takes a lot of work. 
Your field team will be focused on 
synthesizing information and 
reviewing notes. It may be a good 
use of resources to hire a local 
consultant to help obtain 
interview confirmations, manage 
the schedule, and arrange travel 
between interview locations.  
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Once the list of potential key informants is completed, depending on the market, the list may 
need to be validated by IITA or local government counterparts. Feedback at this stage is a great 
way to weed out potential informants to 
create the initial short-list; it won’t be 
possible to interview everyone! When 
creating an interview shortlist, ensure that 
the list covers each region in the market, 
includes actors in each value chain, and 
has a balanced representation of each 
interviewee category mentioned above (see 
lessons learned box). 
 
At the same time you are cutting down the 
list of actors to be interviewed, prepare a 
formal interview request letter (sample 
letter available in the IITA database/toolkit) 
to be sent to potential key informants, especially government stakeholders, as soon as a field 
research plan is approved (sample field research plan available in the IITA database/toolkit). An 
interview request letter may include: introduction to IITA, introduction to Aflasafe, purpose of 
requested interview (you may wish to nuance this for the different categories), who will conduct 
the interview, and suggested timeframe. The request letter would ideally be signed by a senior 
member of IITA or a locally recognized official with the gravitas to ensure a response. Your 
team should make a judgment call on whether to send a formal hard-copy letter or an email, 
depending on the stakeholder/interviewee in question. The letter should also introduce all team 
members who will be conducting interviews and working on the strategy so that there is no 
confusion from interviewees regarding who they are sharing (sometimes sensitive) information 
with, and how the information will be used.  
Step 5. Conduct key informant interviews 
 
Objective Validate hypotheses, verify desk research, fill in gaps, and glean new 
relevant information 
Things to keep in 
mind 
 What is the objective of this interview and what information do we want to 
gather? 
 What follow-up questions should we ask based on findings? 
Projected timeline 
and resources 
1 week to schedule interviews. 1-2 teams (depending on size of market) of 2 
spending approximately 2 weeks in the field. Strategy Manager to lead, 
supported by Associate and/or local consultants (see tips box). Team Leader 
to provide daily feedback on findings 
 
The key informant interviews are the most important data and information source for the final 
commercialization strategy. This is your opportunity to gather raw information from core actors 
in the target market and synthesize it into findings and recommendations for the final 
commercialization strategy. Interviews may also help identify possible investors or other actors 
to be invited to the investor forum.  
 
Lessons Learned  
 
Some governments may have been very involved in trials 
and development and thus see Aflasafe as a public good. 
It is critical that you determine the relationship with 
authorities early to decide when information should be 
shared before launching a key step. Local authorities can 
be a great resource for creating and validating the key 
informant list. In Tanzania, the team created a strategic 
partners team comprising key institutions that had 
supported the development of Aflasafe in Tanzania. 
These institutions were informed of all decision points to 
increase their buy-in to the overall process and ensure 
that their feedback was solicited. 
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rationale for the product from scratch. However, this guide can still be used as a framework for 
how to approach commercialization of other such products, keeping in mind that specific 
process steps or tasks could change considerably.  
Step 1. Define the general market possibilities 
 
Objective Initial brainstorm of types of actors to engage within the sectors and commodities 
impacted by aflatoxins. This will provide a framework for hypothesis generation and 
detailed market segmentation further in the process 
Things to keep in 
mind 
 What product are we selling? 
 Where can Aflasafe be sold? 
Projected timeline 
and resources * 
If this is the first time conducting this exercise, may require a week of pre-work by the 
Strategy Manager or associate to review previous commercialization strategies and 
summary reports on the target country by all participants. The brainstorming exercise 
can be done in a one-day kick-off meeting attended by all members of the strategy 
development team 
*Note that all timelines assume full time commitment by team focused on Aflasafe commercialization. 
New products may require significantly more time 
 
Based on ATTC’s strategy and work to date, the target market 
will almost always be a country’s maize and groundnut value 
chains. As of the writing of this guide, all commercialization 
strategies were written for individual national markets in maize 
and groundnuts, the only exception being Senegal/The Gambia, 
where a single strategy encompasses both countries given their 
many similarities in market dynamics and culture. 
 
Once the target market is defined, the commercialization team 
should gather preliminary information readily available from IITA 
and identify IITA’s present relationships in the target market to 
understand the landscape and enabling environment. In the case 
of a new product, it should be clear from the start who owns the Intellectual Property (IP) (see 
lessons learned box). If it is not clear, then the entire process needs to be paused until the IP 
owner is identified and becomes part of the process. Through the R&D and registration process, 
IITA will have connections in the scientific community and in certain government bodies. 
Importantly, you will know which crops Aflasafe is registered for in-country to begin to focus on 
specific value chains—typically maize, groundnuts, and some cases, soy. There may be many 
hypotheses already developed internally at IITA regarding marketing strategies, sales 
opportunities, and M&D partners; the commercialization team’s job is to verify this speculation 
and their own structured hypotheses with facts and informed assumptions. 
Step 2. Generate hypotheses 
 
Objective Brainstorm the dynamics in the target market to develop initial ideas and research 
framework to be followed for strategy development 
Things to keep in 
mind 
 What do we already know about the market? 
 How does what we know about the market influence demand? 
 What are initial ideas on how to commercialize in the target market 
Projected timeline 
and resources 
1-2 day brainstorm with entire strategy team and other key invitees (IITA members or 
IITA contacts in-country), with at least one person familiar with the agribusiness sector 




Carefully review Aflasafe 
registration information for the 
target country market to 
understand the conditions and 
rights for selling Aflasafe. The 
licensee (IITA) and licensor 
(private investor) could have 
different obligations and rights 
that can greatly affect go-to 
market strategies. 
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The next step in the commercialization strategy development process is to generate hypotheses 
regarding the incentives and risks faced by actors in a value chain if Aflasafe were to be 
introduced. In the context of Aflasafe, the strategy development team should conduct this 
exercise for the crops Aflasafe is registered to treat (maize and groundnuts) within the target 
market. These hypotheses will guide development of the strategy as each hypothesis is 
confirmed, refined, or discarded. The exercise can be conducted in three general steps:  
 
Step 2a. Identify the market actors and potential market segments 
 
Make a list of value chain actors for each of the target crops, carefully considering what types of 
actors can be found at each link of the chain (inputs, production, transport/aggregation, 
processing, retail/export, enabling environment, etc.). Previous commercialization strategies can 
help inform value chain stakeholder lists, but, as all markets have their unique characteristics, 
knowledge of country context at this stage can be useful. 
Time and information permitting, it can be helpful at this 
stage to develop a rudimentary value chain map that 
shows the links between each actor, from input providers 
to consumers, to help visualize the role of each actor in the 
market and hypothesize how they are affected by aflatoxin 
and if they might be willing to pay for Aflasafe. During Step 
3. Desk Research, you may also find detailed value chain 
maps developed by academics or research institutions that 
will serve as important references throughout the 
commercialization process. 
 
Market segmentation is perhaps the most important part of the commercialization strategy, as 
each segment has specific characteristics and addressable demand that will require a unique 
marketing approach. A market segment is any group of actors whose interest in Aflasafe is 
expected to be roughly similar because they all face similar risks and incentives regarding 
aflatoxin. These groups could be defined in terms of actors/buyers with similar interests 
(institutional buyers, such as World Food Program [WFP], national strategic reserves, or public 
sector buyers) or farmers with similar behavior (smallholder farmers consuming on-farm being 
one segment, and large export farms being another), or even a mix. 
 
Attempt to group the market actors you identified into 
different market segments. As more information is 
gathered throughout the commercialization strategy 
process, periodically revisit the segments to evaluate if any 
should be redefined, if a new segment should be added 
after encountering a new market actor, or if actors should 
be regrouped (see lessons learned box).  
 
Step 2b. Prioritize potential buyers  
 
Once the value chain actors and market segments are 
identified, the next step is to estimate the relative size of 
each segment. It is not necessary to precisely quantify the 
size of a market segment at this stage, but rather, 
establish which actors in the value chain handle the largest 
Lessons Learned  
 
Market actor and market segmentation 
information are key reference points 
throughout the process and will provide 
value to the selected investor. Keep 
refining lists of value chain actors, 
notes gathered about behaviors, 
relationships, and pathways for 
sourcing, and pass them on through 
every step in the process. At some 
point, most likely during the business 
case and marketing strategy 
development phases, all of the notes 
will be compiled into value chain maps 
and sourcing pathways.  
Tips and Tricks 
 
Team members should have a rough 
understanding of the agribusiness 
sector of the target market to 
participate effectively in hypothesis 
generation. A little pre-reading will 
make discussions more fruitful and 
lead to higher quality hypotheses. 
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Secondary Influencers 




 Input importers 
 Seed producers 
 Fertilizer traders 
 Input distributors 
 Establish what a reasonable price could be for Aflasafe 
 Identify potential Aflasafe buyers, if any 
 Uncover current challenges in supplying inputs to 
farmers 
 Assess how the market is currently fighting aflatoxin (if 
at all) 
 Identify potential entry-points for Aflasafe sale/ 
distribution 






 USAID Global Bureau’s 
Center for Economic 
Growth and Agriculture 
Development (EGAD) or 
Food Security 
Regional/Country Rep 
 World Food Program 
 Food and Agriculture 
Organization 
 Country office of DFID 
or the country’s other 
major ag-focused 
donor(s) – could be 
BMZ, AfD, DANIDA, etc. 
 Bilateral donor agencies 
 Learn about current aflatoxin awareness levels 
 Identify who is working on aflatoxin solutions 
 Learn if/how the development sector is currently fighting 
aflatoxin 
 Seek out potential opportunities to integrate Aflasafe 
into existing programs  
 Understand how donors/development agencies could 
help engage end-users (i.e., farmers) of Aflasafe 
Non-Profits working 




 International NGOs 
 Local NGOs 
 Learn how farmers are combatting aflatoxin 
 Understand if aflatoxin is a major health issue for 
farmers 
 Learn if NGOs are currently engaged in behavior 
change activities targeting farmers, and / or if such 




 Industry Associations in 
milling, processing, 
poultry, brewery sector 
etc. 
 Determine the current quality requirements for aflatoxin 
 Map who is testing for aflatoxin, how aware are industry 
segments of aflatoxin issues, and how they are tackling 
the issue 
 Assess if buyers are paying a price premium, and if so, 
which buyers 
 Understand strength and relevance of enforcement of 
anti-Aflatoxin regulations 
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Completing desk research will help develop a list of key informants to interview (see tips box). 
Researchers should be sure to keep a record of organizations, 
businesses, or individuals that may be positioned to provide 
nuance and deeper detail on target market dynamics (e.g., those 
who were quoted in a local newspaper article or mentioned in a 
donor report). You will also be able to evaluate what kind of 
information gaps they face, and thus the ones you should focus 
on, after reviewing the information available online. 
 
To help develop interview questions, which will need to be 
adapted to the key informant, attempt to categorize key 
informants and lay out objectives for the interview and/or 
information to be sourced. Some possible categories build upon 
the value chain and market segmentation developed earlier in the process. Illustrative 




Group Type Example Interviewees Objectives 





 National farmer 
organizations for target 
crops 
 Regional farmer 
organizations in areas 
with high aflatoxin 
contamination 
 Large commercial 
farmers 
 Identify possible price point at which Aflasafe would be 
affordable and desirable 
 Determine farm input buying behavior 
 Understand their interest and/or suitability for using an 
aflatoxin solution. Ask if they are already using GAP, 
GHP, or other solutions 
 Discuss risks and incentives that could impact their 
purchase of Aflasafe (especially awareness and 





 Target crop exporters 
 Businesses using target 
crops as key inputs 
(millers, brewing, poultry 
or animal feed, oil cake, 
etc.) 
 Crop aggregators 
 Agricultural warehousing 
or transportation 
businesses 
 Business associations 
e.g, Cereal Millers 
Associations 
 Understand awareness of aflatoxin and interest in a 
solution  
 Identify how aflatoxin impacts their product  
 Understand competitive landscape - what other 
solutions exist to aflatoxin and what is their cost 
 Understand where and how they source their maize or 
groundnuts, and if aflatoxin is a factor 
 Determine if there is a potential for a price premium, or 
other incentives 
 Learn if maize/groundnuts are ever rejected upstream or 
downstream for aflatoxin issues 
 Identify opportunities for directly engaging farmers on 
quality issues through processors/traders 






 Ministry of Agriculture, 
Environment, and/or 
Health and Trade 
 National Food and Drug 
Authority and National 
Standards Bodies 
 Export or Port Authority 
 Understand the government’s awareness of aflatoxin 
 Understand the government’s history in intervention in 
agricultural markets and quality regulation 
 Detail the type of current government involvement that 
could either incentivize aflatoxin control (e.g., through 
testing facilities) or discourage aflatoxin contamination 
(e.g., through revoked certification), as well as 
government appetite for future involvement 
 Discuss risks and incentives that could be addressed to 




Tips and Tricks 
 
The key informant list should be 
modified as interviews progress. 
Ask follow-up questions when 
you hear about new actors that 
may help fill information gaps and 
meet interview objectives. 
Request introductions if possible 
and end all interviews by asking 
who the informant recommends 
you speak with next.  
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segment of the targeted commodity, and thus, which types of actors/segments should be 
prioritized when conducting desk research or planning interviews.  
 
Exhibit 4 shows a sample output of such an exercise. For each stage of the value chain, the 
team made an assumption as to how much of the market’s total maize or groundnuts were 
consumed or handled by a given market segment. The team conducting this exercise then 
hypothesized the level of aflatoxin risk or existing economic incentives to use Aflasafe for that 
market segment. A very important step here is to make a clear distinction between market 
segments that would benefit for non-economic reasons—like health—but might not be willing or 
able to pay versus those that would benefit for economic reasons—like market premiums or 
avoiding government penalties—and thus would be willing to pay. Finally, they prioritized their 
hypotheses as to which segments should be targeted first as potential Aflasafe users.  
 
Exhibit 4. Sample Tanzania Market Segment Prioritization Exercise 
 
 
Once the three steps above are completed, you will have a general framework to follow as data 
is gathered. The goal for the rest of the process is to validate initial hypotheses: validate the 
segments of the market for the target crops, identify risks and incentives related to aflatoxin and 
how they influence behavior for potential purchase of Aflasafe, and prioritize core market 
segments that could drive Aflasafe uptake. As more details are gathered in the steps below, you 
will eventually be able to make a defensible estimation for uptake and design interventions that 
could shift how each key actor perceives Aflasafe risks and incentives to maximize uptake (i.e., 
intervention scenario). 
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Each actor will be impacted differently by Aflasafe. After determining and prioritizing market 
segments, develop hypotheses for how they will perceive the potential incentives or risks of 
Aflasafe’s introduction. These will be different from segment to segment, and could even vary 
among actors within the same segment. Note that these are not general risks and incentives as 
they relate to the wider value chain for the target crops, but are specific to aflatoxins and 
Aflasafe. Some examples to consider are: 
Table 1. Incentives and risks for Aflasafe 
Market Segments 
Category Risk/incentive considerations Examples 
 
Financial 
 Could Aflasafe increase the actor’s 
profitability?  
 Does Aflasafe cost-effectively 
substitute another product or process? 
 Is Aflasafe cost-prohibitive? 
 Price premium paid for quality conscious 
buyers 
 Access to export markets 
 Access to guaranteed market to leverage 
finance for all agricultural inputs 
 Substitute toxin binders that reduce nutrition 
value of feed. For example, in Nigeria, 
analysis revealed that purchasing Aflasafe-
treated maize was cheaper than using toxin 
binders in cases where maize yields were 
greater than 2.5MT/ha – which is slightly 
above the national average yield. 
 Aflatoxin testing requirements 
Moral/Cultural 
 What are local perceptions of 
aflatoxin? 
 How do buyers react to new crop 
treatments and products? 
 Smallholder farmers are reluctant to change 
traditional practices 
 Low awareness of aflatoxin issue 
 Sorghum is valued food to some communities, 
hence using it as an ingredient for Aflasafe 
manufacturing amounts to wasting food. 
Health 
 What is the documented health impact 
of aflatoxin in the market? 
 Is aflatoxin-contaminated feed a local 
issue? 
 The quantity of target market-specific data on 
health impact of aflatoxin 
 Dissemination of aflatoxin health information. 
(For example, in Kenya, there was a recent 
case of acute aflatoxin poisoning causing 
many deaths, and this was covered 
extensively in local papers before the 
commercialization work kicked off.) 
 Existing case studies of effect on livestock 
Regulatory 
 How are aflatoxin levels in products 
regulated, if at all? 
 If levels are regulated, how strong is 
enforcement? 
 Is there any penalty for selling 
contaminated products? 
 Government regulations, and penalties, on 
aflatoxin content in crops or processed goods. 
(For example, in Nigeria, the regulator 
(NAFDAC) imposes strict standards on retail 
sale of aflatoxin-contaminated grains, but 
testing is limited and most retailers are not 
worried about the standards.) 
 Mandatory testing for aflatoxin 
 Subsidies for agricultural inputs 
 VAT exemption 
  
 
Step 2c. Categorize risks and incentives actors may face 
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 Analysis of subsidies, import/export controls, or other government intervention policies 
 Reports of donor-funded projects working in target crops 
 Established price minimums or maximums of crops, inputs, or food 
 Government purchase of surplus or strategic reserves 
Research Question: Who are the major players in the target crop markets? 
 
Potential data sources: 
 Membership of industry associations 
 Recurring names in reports 
Research Question: How much would it cost to set up and run a manufacturing plant? 
 
Potential data sources: 
 Grain or price reports on the cost of white sorghum, for 
example from WFP’s online Food Prices Monthly 
database or market monitoring reports available on 
ReliefWeb 
 Cost estimates from Aflasafe plants in other countries 
(see lessons learned box) 
 Reports on the costs of doing business, such as real 
estate and regional transportation 
 Average salaries for manufacturing workers and 
managers 
Research Question: Does the target market have any unique factors compared to other 
markets? 
 
Potential data sources: 
 Crop season maps and reports 
 Reports and analysis on the history of the maize or groundnut sector 
Desk research should be compiled into a document that is easily referenced and digestible. Key 
pieces of information and figures should be highlighted. More importantly, missing, incomplete, 
or questionable data points should be noted so they may be addressed in the next stage of the 
commercialization strategy process. 
Step 4. Develop Interview List 
 
Objective Determine who can help validate hypotheses and fill data gaps 
Things to keep in 
mind 
 Who can help fill in the information gaps that are unfilled after desk research? 
 What types of categories of actors should we speak to in order to determine how 
to commercialize Aflasafe in the market? 
 How will we schedule and confirm interviews? 
Projected timeline 
and resources 
1 day of preparation/synthesis by Strategy Manager and Associate, followed by 1-2 
week validation period by Team Leader, and possibly Advisory Board, IITA, and other 
stakeholders if applicable.  
 
Lessons Learned  
 
Cost information for the 
manufacturing analysis is difficult 
to gather. Businesses tend to 
consider cost and revenue data as 
proprietary to guard against 
competitors. While some data 
could be found through desk 
research or from interview 
informants, you may need to make 
educated guesses on costs and 
ask investor forum participants to 
validate the assumptions. 
 
Potential data sources: 
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 Crop production maps for maize and groundnuts, and other crops that may be registered 
for Aflasafe treatment 
 Production statistics for key crops. The Food and Agriculture Organization Corporate 
Statistical Database (FAOSTAT) and other databases, along with reports from the 
United States Department of Agriculture (USDA) Global Agriculture Information Network 
(GAIN) can provide data on: 
 Annual production in Metric Tons (MTs) and 
hectares 
 Imports and exports values and quantities 
 National Agricultural Statistics of the target market 
 Ministries of Agriculture annual reports 
 International Organization reports and surveys 
Research Question: Who is producing the target crops, 
and thus would be applying the Aflasafe? 
 
Potential data sources: 
 Research and reports featuring value chain maps, 
such as FAO reports  
 National agricultural statistics 
 Production reports, such as USDA GAIN reports  
 Other sources to determine breakdown of farmers by crop type, size (hectares or MTs), 
and organization membership 
Research Question: Who is buying the target crops, and what are their quality 
expectations (see boxes)? 
 
Potential data sources: 
 Value chain reports (USDA GAIN)  
 Industry association reports for buyers (e.g., milling, processing, brewing, poultry) 
 Project reports (government or donor-funded) working with target crop farmers 
Research Question: How aware is the target market of Aflatoxin? How does this vary 
across market segments and across regions in-country? Is there any testing happening 
in-country? 
 
Potential data sources: 
 Aflatoxin contamination maps 
 IITA and Partnership for Aflatoxin Control in Africa 
(PACA) reports 
 National regulatory body information on ppb thresholds 
 News media 
Research Question: What is the government’s role in 
agricultural markets, particularly for the target crops? 
Tips and Tricks 
 
Availability of reliable information 
online can vary widely across 
markets, particularly those targeted 
by Aflasafe. Research should be 
thorough, but realize that data 
available for one country may not be 
available in another. Gaps should be 
noted, and interview questions 
adjusted accordingly. Keep a tracker 
of different estimates for the same 
data point; in Tanzania, animal feed 
sector production estimates were 
based on a mix of desk research and 
interviews. 
Lessons Learned  
 
Keep an eye on the dates 
associated with each data source. 
For example, a key issue found in 
Tanzania was that the 
contamination maps that were 
available were relatively old, and 
more recent testing results had not 
been published. 
 
Research Question: What is the total addressable demand for Aflasafe?  
 
Potential data sources: 
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Manufacturers/distributors 





 Does Aflasafe have the potential to be 
profitable and scalable? 
 Products similar to Aflasafe have been sold in 
the market 
 Addressable demand appears large enough to 




 How is Aflasafe and aflatoxin viewed 
in the market place? 
 What kind of decontamination rate is 
required to be considered successful? 
 Perception of Aflasafe’s effectiveness in the 
market 




 How difficult is it to access inputs, 
capital, trained human resources, and 
reliable delivery? 
 Enabling environment to start a new business 
line, such as registration process and access 
to credit 
 Human resource availability for lab technicians 
and manufacturing 




 What are your standards for 
production compared to local norms? 
 How involved will local regulatory 
bodies be for Aflasafe production? 
 Role of government in setting up and 
managing a manufacturing plant 




 Are shifts in consumer demand away 
from maize or groundnuts foreseen? 
 Are substitutes to Aflasafe likely in the 
future? 
 Cheaper or more effective substitutes to 
Aflasafe been introduced elsewhere 
 Price shocks for maize and groundnuts 
 National and global consumption trends of 
target crops 
 
Step 3. Desk Research 
 
Objective Gather basic quantitative and qualitative information that can be used to size the 
overall Aflasafe market, estimate uptake, estimate manufacturing costs, and prepare 
for field visits (See sample questions below) 
Things to keep in 
mind 
 Who is the audience for the commercialization strategy?  
 What do they need to know to change behaviors and drive adoption?  
 What questions might a potential investor have about Aflasafe commercialization? 
Projected timeline 
and resources 
3-5 days by Junior Strategy Associate, with subscriptions to the right databases and 
periodicals. 1-2 days of quality control by Strategy Manager and Team Leader 
 
Below are sample research questions that should be explored during desk research, and likely 
sources for obtaining relevant data (see lessons learned boxes): 
 
